The transition from multichannel to omnichannel customer engagement is critical for the industry but not as straightforward as it may seem. Over the years, pharmaceutical companies have tried to make a move, but very few can claim to be successful and having achieved omnichannel maturity. COVID-19 accelerated the digitization drive across industries and demonstrated the potential of virtual interactions and digital marketing. During the pandemic, all large life sciences companies invested in the technologies and teams for omnichannel marketing, and now digital channels live alongside face-to-face customer visits.
Despite this nudge, most pharma companies hit speedbumps in their omnichannel pursuit. The reasons are more than one and arise out of multiple factors, including the following:
- Pharma’s unique business model requiring a different approach to omnichannel marketing
- Need for a unified view of customer data
- Limited patient insights
- Long-term content planning blind spots
- Institutional rigidity
Complete the brief form (to the right) to download the white paper.
You’ll gain insights from:
SVP, Global Head of Commercial Excellence, Grunenthal
Senior Director, Commercial Insights & Analytics,
VP, Worldwide Omnichannel Capabilities,
Bristol Myers Squibb
Senior Director, Head of Sales Innovation, International Operations,
VP, Customer Experience,
Insights & Operations,
Contact us at firstname.lastname@example.org with any questions.